BioCryst Historical Income Statement
| BCRX Stock | USD 4.43 0.07 1.56% |
Historical analysis of BioCryst Pharmaceuticals income statement accounts such as Interest Expense of 113.7 M, Selling General Administrative of 209.6 M or Total Revenue of 348 M can show how well BioCryst Pharmaceuticals performed in making a profits. Evaluating BioCryst Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioCryst Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioCryst Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioCryst Pharmaceuticals is a good buy for the upcoming year.
BioCryst |
About BioCryst Income Statement Analysis
BioCryst Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioCryst Pharmaceuticals shareholders. The income statement also shows BioCryst investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioCryst Pharmaceuticals Income Statement Chart
BioCryst Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting BioCryst's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioCryst Pharmaceuticals revenue and expense. BioCryst Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, BioCryst Pharmaceuticals' Non Operating Income Net Other is fairly stable compared to the past year. Interest Income is likely to rise to about 14.7 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts BioCryst Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioCryst Pharmaceuticals. It is also known as BioCryst Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on BioCryst Pharmaceuticals income statement and represents the costs associated with goods and services BioCryst Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from BioCryst Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Non Operating Income Net Other is fairly stable compared to the past year. Interest Income is likely to rise to about 14.7 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 327.6M | 412.7M | 428.8M | 450.2M | Cost Of Revenue | 7.3M | 6.6M | 6.3M | 9.2M |
BioCryst Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
BioCryst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioCryst Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.9M | 9.4M | 62K | 5.1M | 1.7M | 1.4M | |
| Interest Expense | 11.9M | 14.5M | 59.3M | 99.1M | 108.2M | 113.7M | |
| Selling General Administrative | 37.1M | 61.4M | 113.1M | 144.5M | 199.7M | 209.6M | |
| Total Revenue | 48.8M | 17.8M | 157.2M | 270.8M | 331.4M | 348.0M | |
| Gross Profit | 44.7M | 16.1M | 149.9M | 264.2M | 325.1M | 341.4M | |
| Other Operating Expenses | 148.3M | 192.6M | 334.9M | 419.3M | 435.1M | 456.9M | |
| Operating Income | (99.5M) | (174.8M) | (177.7M) | (148.4M) | (103.7M) | (98.5M) | |
| Ebit | (99.5M) | (174.8M) | (177.7M) | (148.4M) | (103.7M) | (98.5M) | |
| Ebitda | (97.5M) | (165.3M) | (177.7M) | (143.3M) | (102.1M) | (97.0M) | |
| Cost Of Revenue | 4.1M | 1.7M | 7.3M | 6.6M | 6.3M | 9.2M | |
| Total Operating Expenses | 144.2M | 190.9M | 327.6M | 412.7M | 428.8M | 450.2M | |
| Net Income | (120.1M) | (196.6M) | (184.1M) | (247.1M) | (226.5M) | (215.2M) | |
| Income Tax Expense | 11.2M | 13.8M | 2.3M | 2.7M | 310K | 325.5K | |
| Total Other Income Expense Net | (9.4M) | (8.1M) | (4.1M) | (95.9M) | (122.5M) | (128.6M) | |
| Income Before Tax | (108.9M) | (182.8M) | (181.8M) | (244.4M) | (226.2M) | (237.5M) | |
| Research Development | 107.1M | 123.0M | 208.8M | 253.3M | 214.9M | 225.7M | |
| Net Income From Continuing Ops | (108.9M) | (192.2M) | (184.1M) | (247.1M) | (236.3M) | (224.5M) | |
| Non Operating Income Net Other | 2.1M | 2.5M | (3.0M) | 55.1M | 63.4M | 66.6M | |
| Net Income Applicable To Common Shares | (108.9M) | (182.8M) | (184.1M) | (247.1M) | (222.4M) | (211.3M) | |
| Non Recurring | 560K | 471K | 375K | 126K | 113.4K | 107.7K | |
| Interest Income | 1.9M | 9.4M | 62K | 5.1M | 14.0M | 14.7M | |
| Net Interest Income | (10.0M) | (5.1M) | (59.2M) | (94.0M) | (96.1M) | (91.3M) | |
| Reconciled Depreciation | 724K | 748K | 777K | 1.4M | 1.6M | 1.1M |
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with BioCryst Stock
| 0.69 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against BioCryst Stock
| 0.72 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.48 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.